Literature DB >> 26653706

Meta-analysis of downregulated E-cadherin as a poor prognostic biomarker for cervical cancer.

Jifeng Peng1, Shengnan Qi1, Ping Wang1, Wanyu Li1, Lingxie Song1, Chunxia Liu1,2, Feng Li1,2.   

Abstract

AIM: This meta-analysis was conducted to evaluate the diagnostic and prognostic functions of E-cadherin expression in cervical cancer.
METHODS: PubMed and other databases were searched for articles associated with E-cadherin and cervical cancer. These articles were published before June 2015 and written in English or Chinese. Random-effects model was used to pool odds ratios on the heterogeneity test in the meta-analysis.
RESULTS: All of 20 studies were analyzed, in which 522 (42.6%) subjects exhibited reduced E-cadherin expression. Evaluation of clinicopathologic features showed that the downregulation of E-cadherin was related to the overall survival, clinicopathological parameters and age.
CONCLUSION: Downregulation of E-cadherin in cervical cancer patients showed poor overall survival. Therefore, E-cadherinmay be a metastasis-suppressor gene in cervical cancer.

Entities:  

Keywords:  E-cadherin; biomarker; cervical cancer; meta-analysis; prognosis

Mesh:

Substances:

Year:  2015        PMID: 26653706     DOI: 10.2217/fon.15.332

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  9 in total

Review 1.  Meta-analysis of downregulated E-cadherin as a diagnostic biomarker for cervical cancer.

Authors:  Xiaoxia Ma; An Ge; Jie Han; Jin Kang; Yating Zhang; Xiaohong Liu; Li Xing; Xiaochun Liu; Li Dong
Journal:  Arch Gynecol Obstet       Date:  2022-03-13       Impact factor: 2.344

Review 2.  Upregulated N-cadherin expression is associated with poor prognosis in epithelial-derived solid tumours: A meta-analysis.

Authors:  Yong Luo; Ting Yu; Qiongwen Zhang; Qingyu Fu; Yuzhu Hu; Mengmeng Xiang; Haoning Peng; Tianying Zheng; Li Lu; Huashan Shi
Journal:  Eur J Clin Invest       Date:  2018-02-25       Impact factor: 4.686

Review 3.  Dual Role of YY1 in HPV Life Cycle and Cervical Cancer Development.

Authors:  Alicja Warowicka; Justyna Broniarczyk; Martyna Węglewska; Wojciech Kwaśniewski; Anna Goździcka-Józefiak
Journal:  Int J Mol Sci       Date:  2022-03-22       Impact factor: 5.923

4.  Expression of Yin Yang 1 in cervical cancer and its correlation with E-cadherin expression and HPV16 E6.

Authors:  Wanxue Wang; Zhenni Yue; Zhengping Tian; Yiran Xie; Jiamiao Zhang; Yuanping She; Bing Yang; Yuan Ye; Yihua Yang
Journal:  PLoS One       Date:  2018-02-22       Impact factor: 3.240

5.  Differential effects of α-catenin on the invasion and radiochemosensitivity of human colorectal cancer cells.

Authors:  Sarah Förster; Stephanie Hehlgans; Franz Rödel; Benjamin Otto; Nils Cordes
Journal:  Int J Oncol       Date:  2018-02-21       Impact factor: 5.650

6.  lncRNA H19 predicts poor prognosis in patients with melanoma and regulates cell growth, invasion, migration and epithelial-mesenchymal transition in melanoma cells.

Authors:  Gaofeng Shi; Hu Li; Fengshan Gao; Qian Tan
Journal:  Onco Targets Ther       Date:  2018-06-20       Impact factor: 4.147

7.  Diagnostic significance of a color Doppler ultrasound combined with serum CXCL16 and E-cad in cervical cancer.

Authors:  Wenrong Wang; Xing Gao; Yuan Zhu; Yaozhi Qi; Yanjuan Wang
Journal:  Transl Cancer Res       Date:  2021-03       Impact factor: 1.241

8.  Markers of Prognosis for Early Stage Cervical Cancer Patients (Stage IB1, IB2) Undergoing Surgical Treatment.

Authors:  Chen Xu; Tie Ma; Hongzan Sun; Xiaohan Li; Song Gao
Journal:  Front Oncol       Date:  2021-06-02       Impact factor: 6.244

9.  Inhibiting the redox function of APE1 suppresses cervical cancer metastasis via disengagement of ZEB1 from E-cadherin in EMT.

Authors:  Qing Li; Zhi-Wei Zhou; Wei Duan; Cheng-Yuan Qian; Shu-Nan Wang; Meng-Sheng Deng; Dan Zi; Jian-Min Wang; Cheng-Yi Mao; Guanbin Song; Dong Wang; Kenneth D Westover; Cheng-Xiong Xu
Journal:  J Exp Clin Cancer Res       Date:  2021-07-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.